Abstract
Objective. Voxelotor, a FDA-approved drug for the treatment of patients with sickle cell disease (SCD), inhibits hemoglobin S (HbS) polymerization and......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
